Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $14.25, but opened at $14.74. Repare Therapeutics shares last traded at $14.60, with a volume of 2,101 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their target price on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, November 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.50.

Repare Therapeutics Stock Performance

The business has a 50-day moving average of $15.50 and a 200-day moving average of $13.90. The stock has a market capitalization of $634.05 million, a price-to-earnings ratio of -20.70 and a beta of 0.06.

Insider Activity

Hedge Funds Weigh In On Repare Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Repare Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 73,842 shares of the company's stock worth $895,000 after acquiring an additional 600 shares during the period. State Street Corp increased its stake in Repare Therapeutics by 1.2% in the 3rd quarter. State Street Corp now owns 53,475 shares of the company's stock valued at $649,000 after buying an additional 648 shares during the period. Nuveen Asset Management LLC raised its position in Repare Therapeutics by 3.1% during the 3rd quarter. Nuveen Asset Management LLC now owns 21,818 shares of the company's stock worth $265,000 after buying an additional 660 shares during the last quarter. UBS Group AG lifted its stake in shares of Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after acquiring an additional 739 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Repare Therapeutics by 5.3% in the first quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company's stock valued at $356,000 after acquiring an additional 1,253 shares in the last quarter. Hedge funds and other institutional investors own 78.19% of the company's stock.

Repare Therapeutics Company Profile

(Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Further Reading

• Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
• Should You Warm up to Generac Stock for the Winter?
• Is Kintara Therapeutics A Hidden Gem?
• 3 High-Yield Dividend Stocks to Hold for the Long Haul
• Cal-Maine Posts Record Quarter, Remain CALM Income Investors
• Tesla Stock: What the Bulls and the Bears Are Getting Wrong

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.